Immunic (IMUX) Insider Barclay Phillips Buys 25,370 Shares

Barclay Phillips recently purchased 25,370 shares of IMUX on June 29, 2026. This insider transaction occurred alongside several others, indicating a busy period for company insiders.

Insider Buying and Selling at Immunic, Inc.

On June 29, 2026, multiple insiders at IMUX were active in the market. Apart from Barclay Phillips, Jon Congleton acquired 50,740 shares, while Jason Tardio, President and COO, bought 253,000 shares. Glenn Whaley, the Chief Financial Officer, added 120,000 shares to his holdings. Also, Joerg Neermann and Tamar Howson each bought 25,370 shares, and Daniel Vitt acquired 445,000 shares. None of these transactions were part of a pre-planned trading program.

Other Institutional Activity in IMUX

Several institutional investors made significant moves regarding their IMUX holdings. Aberdeen Group PLC reduced its position by 7,419,547 shares, leaving it with 824,394 shares valued at about $9.15 million. BVF Inc/IL similarly cut its holdings by 6,887,675 shares, ending with 765,297 shares worth approximately $8.49 million. Avidity Partners Management LP also decreased its position by 4,029,470 shares, holding 669,941 shares valued at roughly $7.44 million. Meanwhile, Vanguard Capital Management LLC and Soleus Capital Management, L.P. opened new positions with 513,832 and 450,000 shares, valued at $5.70 million and $4.99 million, respectively.

Immunic, Inc. Stock Up 45.1%

Shares of IMUX traded near $15.30 on Tuesday. The stock has experienced fluctuations, with a 52-week low of $10.00 and a high of $20.00. Investors keep an eye on its performance, considering the recent insider activities and institutional movements.

Analysts Set New Price Targets

Analyst firms have been active in setting targets for IMUX. On May 22, 2026, B. Riley Securities maintained a buy rating with a price target of $27.00. HC Wainwright & Co. also maintained a buy rating, targeting $22.00 on April 30, 2026. Stifel initiated coverage with a buy rating and a $2.50 target on April 17, 2026. The overall consensus remains positive with a focus on growth potential.

Bottom Line

The recent insider transactions at IMUX, including Barclay Phillips' purchase, highlight increased insider confidence in the company. While the stock price remains volatile, the activity from both insiders and institutions suggests a dynamic period for IMUX. Investors often watch these moves for insights, but it's essential to remember that these filings are backward-looking and may not reflect the current situation.